抗体药物复合体（ADC）市场规模、份额和成长分析：按产品、标靶、技术、应用和地区划分－2026-2033年产业预测

2024年全球抗体药物复合体（ADC）市值为120.7亿美元，预计将从2025年的131.3亿美元成长到2033年的257.8亿美元。预测期（2026-2033年）的复合年增长率预计为8.8%。

随着全球癌症发病率上升和对创新药物的需求不断增长，抗体药物复合体（ADC）的销售额预计将显着增长。此外，生物製药研发投入的增加以及ADC开发技术的进步也推动了市场发展。加快核准流程以促进市场准入，预计也将对ADC的销售产生正面影响。此外，个人化医疗的兴起和广泛应用也将支持市场扩张。然而，高昂的研发成本、与毒性相关的安全隐患以及来自生物相似药的竞争等挑战，对抗体药物复合体领域的企业而言都是重要的阻碍因素，并可能阻碍市场的整体成长。

抗体药物复合体(ADC) 市场按产品、标靶、应用、技术和地区进行细分。依产品划分，可分为 Cadsila、Enhertz、Adcetris、Padsev、Troderbi、Polibi 等公司。依应用划分，可分为血液肿瘤、乳癌、尿路上皮癌/膀胱癌和其他癌症。依标靶划分，可分为 HER2、CD22、CD30 等。依技术划分，可分为可裂解连接子、不可裂解连接子、无连接子、连接子技术类型、酬载技术等。依地区划分，可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

全球抗体药物复合体（ADC）市场驱动因素

全球抗体药物复合体(ADC) 市场正受到抗体工程、连接子化学和细胞毒性有效载荷领域重大创新的推动，这些创新正引领着新型高效抗体药物复合体的开发。增强的偶联技术实现了位点特异性药物连接，从而提高了稳定性并降低了免疫抗原性。此外，各公司正在推动不可裂解连接子、双药 ADC 和双特异性抗体的研究，以应对抗药性问题。这些进展对于扩大治疗范围、扩大适应症和最大限度地减少副作用至关重要，最终将改变抗体药物复合体疗法的模式。

全球抗体药物复合体（ADC）市场的限制因素

全球抗体药物复合体（ADC）市场面临许多可能阻碍其成长的重大挑战。 ADC的生产製造需要复杂的设计、开发和生产流程，需要专门的设施进行抗体生成、细胞毒性药物管理和偶联操作。这种复杂性需要大量的资本投入，从而构成准入障碍。此外，严格的临床前和临床试验阶段对于确保安全性和有效性至关重要，导致研发成本高。这些因素综合起来可能会限制抗体药物复合体在市场上的渗透率和整体扩张。

全球抗体药物复合体（ADC）市场趋势

全球抗体药物复合体(ADC) 市场正呈现出一个显着的趋势，即各公司正将其研发范围扩展到癌症治疗以外的领域。儘管传统上 ADC 的研发重点是癌症治疗，但人们对利用靶向特定免疫细胞的 ADC 来精准递送免疫调节剂的兴趣日益浓厚，尤其是在狼疮和类风湿性关节炎等自体免疫疾病方面。此外，利用标靶病原体特异性标记物的 ADC 对抗细菌感染疾病的研究也不断推进。 ADC 应用的多元化有望提升产生收入，并扩大这些创新生物製药在多种疾病领域的治疗效果。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球抗体药物复合体（ADC）市场规模：按产品和复合年增长率划分（2026-2033 年）

• 门头
• 恩哈特
• 阿德塞特里斯
• 帕德塞夫
• 特罗德尔比
• 波利维
• 其他的

全球抗体药物复合体（ADC）市场规模：以标靶和复合年增长率划分（2026-2033 年）

• HER2
• CD22
• CD30

全球抗体药物复合体（ADC）市场规模：按应用和复合年增长率划分（2026-2033 年）

• 血癌
• 乳癌
• 尿路上皮癌
• 膀胱癌
• 其他癌症

全球抗体药物复合体（ADC）市场规模：按技术和复合年增长率划分（2026-2033 年）

• 连接技术
  • 可切割连接器
  • 非切割连接子
  • 无连接器
• 有效载荷技术

全球抗体药物复合体（ADC）市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Seagen, Inc.
• Takeda Pharmaceutical Company Ltd.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• Daiichi Sankyo Company Ltd.
• GlaxoSmithKline Plc
• Astellas Pharma, Inc.
• ADC Therapeutics SA
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc.
• Sanofi
• Incyte Corporation
• Janssen Pharmaceuticals（Johnson & Johnson）
• Servier Laboratories
• Regeneron Pharmaceuticals, Inc.
• Immunogen, Inc.

结论与建议

Global Antibody Drug Conjugates (ADC) Market size was valued at USD 12.07 Billion in 2024 and is poised to grow from USD 13.13 Billion in 2025 to USD 25.78 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

The increasing incidence of cancer globally, coupled with a growing demand for innovative pharmaceuticals, is anticipated to significantly boost the sales of antibody drug conjugates (ADCs). The market is further propelled by heightened investments in biopharmaceutical research and technological advancements in ADC development. Expedited approval processes designed to accelerate market entry are expected to positively impact ADC sales as well. Additionally, the rising trend towards personalized medicine and its wider adoption will support market expansion. However, challenges such as high development costs, safety concerns related to toxicity, and competition from biosimilars pose notable constraints for companies operating in the antibody drug conjugate sector, potentially hindering overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (ADC) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates (ADC) Market Segments Analysis

The Antibody Drug Conjugates (ADC) Market is segmented based on the product, target, application, technology, and region. Based on the product, the Antibody Drug Conjugates (ADC) Market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others. Based on the application, the market is segmented into blood cancer,breast cancer, urothelial cancer & bladder cancer, and other cancer. Based on the target, the market is segmented into HER2, CD22, CD30, and others. On the basis of technology, the market is divided into cleavable linker, non-cleavable linker, linkerless, linker technology type, payload technology, and others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Driver of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is propelled by significant innovations in antibody engineering, linker chemistry, and cytotoxic payloads, which have resulted in the development of new and effective antibody drug conjugates. Enhanced conjugation techniques facilitate site-specific drug attachment, leading to improvements in stability and a reduction in immunogenicity. In addition, companies are investigating non-cleavable linkers, dual-drug ADCs, and bispecific antibodies as strategies to combat resistance. These advancements are crucial in expanding therapeutic windows, widening treatment indications, and minimizing adverse effects, ultimately transforming the landscape of antibody drug conjugate therapies.

Restraints in the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market faces several significant challenges that may hinder its growth. The production of ADCs necessitates complex design, development, and manufacturing processes, which require specialized facilities tailored for antibody generation, cytotoxic drug management, and conjugation procedures. This complexity results in substantial capital investments that can be a barrier to entry. Furthermore, the high costs associated with research and development due to rigorous preclinical and clinical testing phases are essential for ensuring safety and efficacy. These combined factors could limit the widespread adoption and overall expansion of antibody drug conjugates in the market.

Market Trends of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is witnessing a notable trend as companies expand their research and development efforts beyond oncology applications. While traditionally focused on cancer treatments, there is a growing interest in leveraging ADCs for various indications, particularly autoimmune disorders such as lupus and rheumatoid arthritis, by targeting specific immune cells for precise delivery of immunomodulatory agents. Furthermore, research is being directed towards combating bacterial infections through the targeting of pathogen-specific markers. This diversification of ADC applications is poised to enhance revenue generation and broaden the therapeutic impact of these innovative biopharmaceuticals across multiple disease areas.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Antibody Drug Conjugates (ADC) Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Global Antibody Drug Conjugates (ADC) Market Size by Target & CAGR (2026-2033)

• Market Overview
• HER2
• CD22
• CD30

Global Antibody Drug Conjugates (ADC) Market Size by Application & CAGR (2026-2033)

• Market Overview
• Blood Cancer
• Breast Cancer
• Urothelial Cancer
• Bladder Cancer
• Other Cancer

Global Antibody Drug Conjugates (ADC) Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Linker Technology
  • Cleavable Linker
  • Non-Cleavable Linker
  • Linkerless
• Payload Technology

Global Antibody Drug Conjugates (ADC) Market Size & CAGR (2026-2033)

• North America (Product, Target, Application, Technology)
  • US
  • Canada
• Europe (Product, Target, Application, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Target, Application, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Target, Application, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Target, Application, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Seagen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADC Therapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations